Hormonal
Dapagliflozin (SGLT2 inhibitor) provides glycemic control equivalent to glipizide (sulfonylurea) while inducing significant weight loss and reducing hypoglycemia risk in type 2 diabetes patients inadequately controlled on metformin.
If you are taking metformin and your blood sugar is not controlled, adding Dapagliflozin can help lower your HbA1c just as effectively as Glipizide, but without the typical side effects of weight gain and low blood sugar. It works by removing excess sugar through urine. Be aware of a slightly higher risk of genital infections, which are usually treatable.
Despite similar 52-week glycemic efficacy, dapagliflozin reduced weight and produced less hypoglycemia than glipizide in type 2 diabetes inadequately controlled with metformin.
Why this rating
Randomized, double-blind, active-controlled, noninferiority trial with 801 patients over 52 weeks.
Source
Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin
Michael A. Nauck et al. · Diabetes Care · 2011
DOI 10.2337/dc11-0606
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →